ChemoCentryx Inc (CCXI) : Vivo Capital has sold out all of its stake in ChemoCentryx Inc during the most recent quarter, according to the disclosure filed by the company on Aug 15, 2016 with the SEC. The investment management company has sold out 887,906 shares of ChemoCentryx Inc which is valued at $3,835,754.
Other Hedge Funds, Including , Schwab Charles Investment Management Inc reduced its stake in CCXI by selling 3,000 shares or 8.57% in the most recent quarter. The Hedge Fund company now holds 32,000 shares of CCXI which is valued at $138,240.Citadel Advisors reduced its stake in CCXI by selling 3,668 shares or 5.18% in the most recent quarter. The Hedge Fund company now holds 67,085 shares of CCXI which is valued at $289,807.Rhumbline Advisers reduced its stake in CCXI by selling 2,689 shares or 9.39% in the most recent quarter. The Hedge Fund company now holds 25,946 shares of CCXI which is valued at $112,087. Royce Associates Lp sold out all of its stake in CCXI during the most recent quarter. The investment firm sold 32,900 shares of CCXI which is valued $135,219. Acadian Asset Management added CCXI to its portfolio by purchasing 4,771 company shares during the most recent quarter which is valued at $22,137.
ChemoCentryx Inc opened for trading at $5.02 and hit $5.31 on the upside on Thursday, eventually ending the session at $5.29, with a gain of 5.80% or 0.29 points. The heightened volatility saw the trading volume jump to 2,22,569 shares. Company has a market cap of $253 M.
ChemoCentryx Inc. (ChemoCentryx) is a biopharmaceutical company. The Company is focused on discovering developing and commercializing orally-administered therapeutics to treat autoimmune diseases inflammatory disorders and cancer. It targets the chemoattractant system which is a network of molecules including chemokine ligands and their associated receptors as well as related chemoattractant receptors. Each of its drug candidates is a small molecule designed to target a specific chemokine or chemoattractant receptor thereby blocking the inflammatory response driven by that particular chemokine while leaving the rest of the immune system unaffected. The Company’s product portfolio includes CCX140 CCX872 CCX168 Vercirnon (Traficet-EN or CCX282) and CCX507.